Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px
Organisation › Details

Arpida AG (SWX: ARPN)

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities near Basel, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance.

Arpida's leading product candidate is intravenous iclaprim, a broad-spectrum antibiotic that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The US Food and Drug Administration has granted fast track status to intravenous iclaprim. In July 2007, Arpida reported the completion of the Phase III programme in complicated skin and skin structure infections. An NDA filing is expected to take place in the second half of 2007.

In June 2007, Arpida announced that it has received approval from the US FDA to initiate Phase II trials with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP). An oral formulation of iclaprim has successfully completed three Phase I trials: an ADME study (absorption, distribution, metabolism and excretion) with radiolabelled compound, a Phase I bioavailability trial with a solution and one with a capsule formulation. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch should be a valuable instrument in reducing healthcare costs and enhancing patient comfort. Arpida's fourth most advanced programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007. An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be highly effective in eradicating pathogens in preclinical models of skin infection and nasal carriage. Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages *

 

Period Start 1997-07-01 established
Period End  renamed
  Group Evolva (Group)
  Today Evolva Holding SA (SIX: EVE)
  Successor Evolva Holding SA (SIX: EVE)
Product Industry anti-infective drug
     
Region Region Reinach BL
  Country Switzerland
  Street 23 Duggingerstr.
  City 4153 Reinach BL
  Tel +41-61-4179-660
    Address record changed: 2018-07-24
     
Basic data Employees C: 51 to 100 (2008-10-01)
  Currency CHF
  Annual sales 200,000 (revenue (2007) 2007-12-31)
  Profit -59,100,000 (2007-12-31)
  Cash 68,100,000 (2007-12-31)
     
    * Document for �About Section�: 
     
   
Record changed: 2017-04-01

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Evolva (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px




» top